BR112014028643A8 - Profármaco de alta penetração, seus usos, e composição farmacêutica - Google Patents

Profármaco de alta penetração, seus usos, e composição farmacêutica

Info

Publication number
BR112014028643A8
BR112014028643A8 BR112014028643A BR112014028643A BR112014028643A8 BR 112014028643 A8 BR112014028643 A8 BR 112014028643A8 BR 112014028643 A BR112014028643 A BR 112014028643A BR 112014028643 A BR112014028643 A BR 112014028643A BR 112014028643 A8 BR112014028643 A8 BR 112014028643A8
Authority
BR
Brazil
Prior art keywords
high penetration
hpps
generate
pharmaceutical composition
hpcs
Prior art date
Application number
BR112014028643A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112014028643A2 (pt
Inventor
Chongxi Yu
Lina Xu
Original Assignee
Chongxi Yu
Techfields Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chongxi Yu, Techfields Pharma Co Ltd filed Critical Chongxi Yu
Publication of BR112014028643A2 publication Critical patent/BR112014028643A2/pt
Publication of BR112014028643A8 publication Critical patent/BR112014028643A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/625—Salicylic acid; Derivatives thereof having heterocyclic substituents, e.g. 4-salicycloylmorpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G05—CONTROLLING; REGULATING
    • G05B—CONTROL OR REGULATING SYSTEMS IN GENERAL; FUNCTIONAL ELEMENTS OF SUCH SYSTEMS; MONITORING OR TESTING ARRANGEMENTS FOR SUCH SYSTEMS OR ELEMENTS
    • G05B19/00—Program-control systems
    • G05B19/02—Program-control systems electric
    • G05B19/18—Numerical control [NC], i.e. automatically operating machines, in particular machine tools, e.g. in a manufacturing environment, so as to execute positioning, movement or co-ordinated operations by means of program data in numerical form
    • G05B19/409—Numerical control [NC], i.e. automatically operating machines, in particular machine tools, e.g. in a manufacturing environment, so as to execute positioning, movement or co-ordinated operations by means of program data in numerical form characterised by using manual data input [MDI] or by using control panel, e.g. controlling functions with the panel; characterised by control panel details or by setting parameters
    • G—PHYSICS
    • G05—CONTROLLING; REGULATING
    • G05B—CONTROL OR REGULATING SYSTEMS IN GENERAL; FUNCTIONAL ELEMENTS OF SUCH SYSTEMS; MONITORING OR TESTING ARRANGEMENTS FOR SUCH SYSTEMS OR ELEMENTS
    • G05B2219/00—Program-control systems
    • G05B2219/30—Nc systems
    • G05B2219/33—Director till display
    • G05B2219/33192—Radio link, wireless

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Automation & Control Theory (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Manufacturing & Machinery (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Human Computer Interaction (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
BR112014028643A 2012-01-18 2013-03-15 Profármaco de alta penetração, seus usos, e composição farmacêutica BR112014028643A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201210151555 2012-01-18
CN201210151555.7 2012-05-16
PCT/CN2013/072693 WO2013170655A1 (en) 2012-01-18 2013-03-15 High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions

Publications (2)

Publication Number Publication Date
BR112014028643A2 BR112014028643A2 (pt) 2021-08-03
BR112014028643A8 true BR112014028643A8 (pt) 2021-11-03

Family

ID=49583088

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014028643A BR112014028643A8 (pt) 2012-01-18 2013-03-15 Profármaco de alta penetração, seus usos, e composição farmacêutica

Country Status (17)

Country Link
US (4) US11857545B2 (enExample)
EP (2) EP2849738B1 (enExample)
JP (2) JP6445967B2 (enExample)
KR (6) KR102232625B1 (enExample)
CN (4) CN116898848A (enExample)
AU (2) AU2013262320B2 (enExample)
BR (1) BR112014028643A8 (enExample)
CA (2) CA3189252A1 (enExample)
ES (1) ES2969344T3 (enExample)
HK (1) HK1207562A1 (enExample)
IN (1) IN2014KN02583A (enExample)
MX (1) MX378183B (enExample)
PL (1) PL2849738T3 (enExample)
RU (1) RU2683934C2 (enExample)
TW (1) TWI658836B (enExample)
WO (1) WO2013170655A1 (enExample)
ZA (1) ZA201407777B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3725311A1 (en) 2014-02-10 2020-10-21 Respivant Sciences GmbH Methods for the treatment of lung diseases with mast cell stabilizers
EP3653207A1 (en) 2014-02-10 2020-05-20 Respivant Sciences GmbH Mast cell stabilizers treatment for systemic disorders
NO2723977T3 (enExample) * 2014-03-19 2018-03-10
EP3331522A1 (en) 2015-08-07 2018-06-13 Patara Pharma LLC Methods for the treatment of mast cell related disorders with mast cell stabilizers
US10265296B2 (en) 2015-08-07 2019-04-23 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
CN110139646A (zh) 2016-08-31 2019-08-16 瑞思皮万特科学有限责任公司 用于治疗由特发性肺纤维化引起的慢性咳嗽的色甘酸组合物
WO2018067341A1 (en) 2016-10-07 2018-04-12 Patara Pharma, LLC Cromolyn compositions for treatment of pulmonary fibrosis
CN112074270A (zh) * 2018-05-10 2020-12-11 学校法人庆应义塾 前列腺癌的预防或治疗剂
JP7759693B2 (ja) 2018-09-14 2025-10-24 ジャンイン ユスン ファーマシューティカル カンパニー，リミテッド モンテルカストおよびペプチドの新規接合体
CA3130291A1 (en) * 2019-03-27 2020-10-01 Anthony P. FORD Beta adrenergic agonist and methods of using the same
US20230124467A1 (en) * 2020-03-03 2023-04-20 Mios Pharmaceuticals Limited Compounds and methods for treating diseases and/or conditions caused by coronavirus
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
CN113933401B (zh) * 2020-06-29 2023-07-21 重庆华邦制药有限公司 分离检测阿伐斯汀中间体z3中基因毒性杂质的方法
CN114409673B (zh) * 2022-01-04 2023-08-08 广东克冠达医药科技有限公司 一种吗啡喃类化合物及其制备方法与应用
JP2025504447A (ja) * 2022-01-17 2025-02-12 テックフィールズ インコーポレイテッド アスピリン及びその他のｎｓａｉｄの高透過プロドラッグによる心血管疾患の予防又は治療
AU2023207742A1 (en) * 2022-01-17 2024-08-29 Techfields Inc. Treatment of signs, symptoms and/or complications of viral, bacterial, protozoal, and/or fungal infections by high penetration prodrugs

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB100208A (en) 1915-03-24 1917-03-01 Isidore Swientoslawsk Morrison Improvements in Watch Movements.
US2694063A (en) 1949-07-07 1954-11-09 Leo Pharm Prod Ltd Quaternary ammonium addition salts of penicillin esters
US2694031A (en) 1949-07-07 1954-11-09 Leo Pharm Prod Ltd Hydroiodides of amino esters of penicillin and oil composition thereof
US2694061A (en) 1949-07-07 1954-11-09 Leo Pharm Prod Ltd Method of producing aminoalcohol esters of penicillin
US2671805A (en) 1952-07-02 1954-03-09 Searle & Co Basically substituted o-arylamino-benzamides
GB759603A (en) 1952-07-10 1956-10-24 Yvan Villax Method for the production of esters of penicillin
GB768347A (en) 1953-02-06 1957-02-13 Knud Abildgaard Sulphanilate salts of amino alcohol esters of penicillin
GB984471A (en) 1961-01-12 1965-02-24 Parke Davis & Co Anthranilic acid esters and methods for producing the same
CH399486A (fr) 1962-10-02 1965-09-30 Biosedra Lab Procédé de préparation de nouvelles salicylamides
US3365483A (en) 1963-06-05 1968-01-23 Starogardzkie Zakl Farma Process for obtaining diethylaminoethanol acetylsalicylate hydrochloride
US3420871A (en) 1964-09-01 1969-01-07 Parke Davis & Co Anthranilic acid esters
FR5342M (enExample) 1966-03-08 1967-09-04
DK121236B (da) 1967-07-03 1971-09-27 Gea As Analogifremgangsmåde til fremstilling af terapeutisk aktive, basisk substituerede amider af N-substituerede antranilsyrer, eller syreadditionssalte deraf.
GB1187259A (en) 1967-10-23 1970-04-08 Hexachimie New Aminoalkyl Esters of 2-Anilino-Nicotinic Acids and process for their manufacture
US3956363A (en) 1969-08-08 1976-05-11 Merck & Co., Inc. Substituted indenyl acetic acids
US3957764A (en) 1969-11-11 1976-05-18 Lovens Kemiske Fabrik Produktionsaktieselskab 6-aminopenicillanic acid derivatives
CA996929A (en) 1971-04-05 1976-09-14 Kohzi Nakano Acyloxyalkyl ester derivatives of penicillin
GB1335317A (en) 1971-06-23 1973-10-24 Leo Pharm Prod Ltd Cephalosporin esters salts thereof and methods for their pre paration
US3966923A (en) 1972-06-05 1976-06-29 Pierre Fabre S.A. Medicaments intended for the prevention and treatment of ischemic disturbances
US4006181A (en) 1972-07-27 1977-02-01 Pierre Fabre S.A. Process for the obtaining of esters of acetylsalicylic acid and amino alcohols
US3914811A (en) 1972-07-31 1975-10-28 Jonathan Francis Lightweight, compact air mattress with improved casing and inflatable members
ES428213A1 (es) 1974-07-12 1976-07-16 Andreu Sa Dr Procedimiento para la obtencion de esteres dialquilaminoal-quilicos de penicilina.
US4012508A (en) 1975-02-03 1977-03-15 Burton Verna M Topical composition and method
FR2348701A1 (fr) 1976-04-22 1977-11-18 Hexachimie Nouveau derive du p-acetamidophenol,sa preparation et son utilisation en therapeutique
US4150157A (en) 1976-06-11 1979-04-17 Beecham Group Limited Penicillin compositions
US4215120A (en) 1977-07-14 1980-07-29 Beecham Group Limited Penicillin esters and their preparation
AU518216B2 (en) 1977-09-06 1981-09-17 Hafslund Nycomed Pharma Aktiengesellschaft Thienothiazine derivatives
US4206220A (en) 1978-07-13 1980-06-03 Interx Research Corporation Prodrugs for the improved delivery of non-steroidal anti-inflammatory agents
US4244948A (en) 1979-05-07 1981-01-13 Allergan Pharmaceuticals, Inc. Medical use of esters of acetylsalicylic acid to treat acne
IN153407B (enExample) 1979-09-28 1984-07-14 Ciba Geigy Ag
DE3023206A1 (de) 1979-11-02 1982-01-14 Efeka Friedrich & Kaufmann GmbH & Co KG, 3000 Hannover Indometacin-ester, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
JPS57183738A (en) 1981-05-06 1982-11-12 Yamanouchi Pharmaceut Co Ltd Aromatic carboxylic acid derivative
JPS5852291A (ja) 1981-09-22 1983-03-28 Kureha Chem Ind Co Ltd ペニシリン系抗生物質誘導体とその医薬剤
FR2542998B1 (fr) 1983-03-24 1986-01-31 Rhone Poulenc Sante Nouvelle forme transdermale du dinitrate d'isosorbide
US4640689A (en) 1983-08-18 1987-02-03 Drug Delivery Systems Inc. Transdermal drug applicator and electrodes therefor
DE3347128A1 (de) 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen 9-halogen-(delta)(pfeil hoch)2(pfeil hoch)-prostaglandinderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
EP0152379A3 (de) 1984-02-15 1986-10-29 Ciba-Geigy Ag Verfahren zur Herstellung von pharmazeutischen Zusammensetzungen enthaltend unilamellare Liposomen
GB2157284B (en) 1984-04-11 1987-11-04 Leo Pharm Prod Ltd 6-b-halopenicillanic acid salts
GB8511988D0 (en) 1985-05-11 1985-06-19 Beecham Group Plc Compounds
US4822773A (en) 1985-06-28 1989-04-18 Merck & Co., Inc. Enhancement of absorption of drugs from gastrointestinal tract using choline ester salts
IT1213579B (it) 1986-07-03 1989-12-20 Angelo Signor Marino Nicolini Flogistica. esteri di salsalato con guaiacolo atti al trattamento di broncopneumapatie a base
AU1508988A (en) 1987-04-27 1988-10-27 Syntex Pharmaceuticals International Ltd. Omega-quaternary ammonium alkyl esters and thioesters of acidic nonsteroidal antiinflammatory drugs
US5321020A (en) 1989-03-28 1994-06-14 Pfizer Inc. Antibacterial 2-carbapenem derivatives
JP2672363B2 (ja) 1989-03-29 1997-11-05 帝人株式会社 有機非線形光学材料
US5760261A (en) 1990-02-28 1998-06-02 Guttag; Alvin Higher fatty acid derivatives of salicylic acid and salts thereof
US5109011A (en) 1990-07-30 1992-04-28 Hoechst-Roussel Pharmaceuticals Incorporated P-acylaminophenoxycarbamates and derivatives
JPH07500113A (ja) 1991-10-16 1995-01-05 リチャードソン、ビックス、インコーポレーテッド 薬物の改善された局所送達用の高皮膚浸透系
HRP921157A2 (en) 1991-12-20 1994-10-31 Lohmann Therapie Syst Lts Transdermal system of applying acetilsalicilyc acid in antithrombosys therapy
US5629019A (en) 1992-02-27 1997-05-13 Alza Corporation Formulations with hydrophobic permeation enhancers
US5190953A (en) 1992-03-26 1993-03-02 A. H. Robins Company, Incorporated Heterocyclic carboxylic acid amides and esters of azabicyclic compounds as gastric prokinetic, antiemetic, anxiolytic and antiarrhythmic agents
US5300512A (en) 1992-06-24 1994-04-05 G. D. Searle & Co. Benzimidazole compounds
WO1994010167A1 (en) 1992-10-30 1994-05-11 Merck Sharp & Dohme Limited Tachykinin antagonists
US5399562A (en) 1994-02-04 1995-03-21 G. D. Searle & Co. Indolones useful as serotonergic agents
GB9404756D0 (en) 1994-03-11 1994-04-27 Knx Limited Data output control
JPH10502102A (ja) 1994-06-14 1998-02-24 スミスクライン・ビーチャム・コーポレイション 固体合成用樹脂
US5626838A (en) 1995-03-13 1997-05-06 The Procter & Gamble Company Use of ketorolac for treatment of squamous cell carcinomas of the oral cavity or oropharynx
US5654337A (en) 1995-03-24 1997-08-05 II William Scott Snyder Topical formulation for local delivery of a pharmaceutically active agent
AUPN531195A0 (en) 1995-09-11 1995-10-05 J.W. Broadbent Nominees Pty. Ltd. Lipid extract having anti-inflamatory activity
US5570559A (en) 1995-09-26 1996-11-05 Lewis; Thomas D. Fall arrestor
DK0898477T3 (da) 1996-05-10 2003-03-24 Upjohn Co Topisk indgivelse af prenafloxcin til behandlingen af systemiske bakterielle sygdomme
US5929086A (en) 1996-05-10 1999-07-27 Pharmacia & Upjohn Company Topical administration of antimicrobial agents for the treatment of systemic bacterial diseases
IT1282736B1 (it) 1996-05-21 1998-03-31 Angelini Ricerche Spa Uso di derivati del p-amminofenolo per preparare composizioni farmaceutiche utili nel trattamento di malattie neurodegenerative
KR100213465B1 (ko) 1996-11-01 1999-08-02 최좌진 케토프로펜 패취 조성물
US6011049A (en) 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
ATE446748T1 (de) 1997-03-10 2009-11-15 Univ Loma Linda Med Verwendung von r-carprofen zur vorbeugung der alzheimerschen krankheit
US6451815B1 (en) 1997-08-14 2002-09-17 Aventis Pharmaceuticals Inc. Method of enhancing bioavailability of fexofenadine and its derivatives
US5885597A (en) 1997-10-01 1999-03-23 Medical Research Industries,Inc. Topical composition for the relief of pain
AU735704B2 (en) 1998-01-29 2001-07-12 Bristol-Myers Squibb Company Derivatives of 1,3,4-oxadiazolone
MXPA00012844A (es) 1998-07-07 2004-05-21 Transdermal Technologies Inc Composiciones para la liberacion transdermica rapida y sin irritacion de agentes farmaceuticamente activos y metodos para formular tales composiciones y liberar los mismos.
US20030087962A1 (en) 1998-10-20 2003-05-08 Omeros Corporation Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation
SE9900941D0 (sv) 1998-12-23 1999-03-16 Nomet Management Serv Bv Novel retinoic acid derivatives and their use
WO2000067754A1 (en) 1999-05-12 2000-11-16 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
US6368618B1 (en) 1999-07-01 2002-04-09 The University Of Georgia Research Foundation, Inc. Composition and method for enhanced transdermal absorption of nonsteroidal anti-inflammatory drugs
US6669951B2 (en) * 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
WO2001052823A2 (en) 2000-01-20 2001-07-26 Noven Pharmaceuticals, Inc. Compositions to effect the release profile in the transdermal administration of drugs
US6429223B1 (en) 2000-06-23 2002-08-06 Medinox, Inc. Modified forms of pharmacologically active agents and uses therefor
DE10034802A1 (de) 2000-07-18 2002-01-31 Bayer Ag Stabile Salze von O-Acetylsalicylsäure mit basischen Aminosäuren
US6416772B1 (en) 2001-01-12 2002-07-09 H. Wayne Van Engelen Topical dermal anaesthetic
US6528040B1 (en) 2001-01-18 2003-03-04 Maurine Pearson EMU oil-based formulations for use as an analgesic, anesthetic and antipruritic
ITMI20010395A1 (it) 2001-02-27 2002-08-27 Dompe Spa Omega-amminoalchilammidi di acidi r-2-aril-propionici come inibitori della chemiotassi di cellule polimorfonucleate e mononucleate
WO2003022270A1 (en) 2001-09-13 2003-03-20 Noven Pharmaceuticals, Inc. Transdermal administration of an enalapril ester
AU2002347906A2 (en) 2001-10-16 2003-04-28 Hypnion, Inc. Treatment of CNS disorders using CNS target modulators
US20030143165A1 (en) 2002-01-25 2003-07-31 Allan Evans NSAID-containing topical formulations that demonstrate chemopreventive activity
ITMI20021399A1 (it) 2002-06-25 2003-12-29 Nicox Sa Inibitori della cicloossigenasi 2
EP1534672B1 (en) 2002-07-23 2013-05-01 Ardenia Investments Ltd. Retinol derivatives, their use in the treatment of cancer and for potentiating the efficacy of other cytotoxic agents
RU2332425C2 (ru) * 2002-09-06 2008-08-27 Инсёрт Терапьютикс, Инк. Полимеры на основе циклодекстрина для доставки терапевтических средств
KR101476067B1 (ko) 2002-09-06 2014-12-23 인설트 테라페틱스, 인코퍼레이티드 공유결합된 치료제 전달을 위한 사이클로덱스트린-기초 중합체
US20040109826A1 (en) * 2002-12-06 2004-06-10 Dey, L.P. Stabilized albuterol compositions and method of preparation thereof
ZA200507284B (en) 2003-03-12 2007-03-28 Celgene Corp 7-amino-isoindolyl compounds and their pharmaceutical uses
US7052715B2 (en) 2003-04-11 2006-05-30 All Natural Fmg, Inc. Alcohol-free transdermal analgesic composition and processes for manufacture and use thereof
BRPI0411347A (pt) 2003-06-10 2006-07-11 Pfizer combinações terapêuticas compreendendo inibidores de pde e antagonistas dos receptores de vasopressina para o tratamanento de dismenorréia
US8173840B2 (en) * 2003-07-29 2012-05-08 Signature R&D Holdings, Llc Compounds with high therapeutic index
KR20060073584A (ko) 2003-07-29 2006-06-28 시그너쳐 알 앤드 디 홀딩스, 엘엘씨 아미노산 프로드럭
DE10335726A1 (de) 2003-08-05 2005-03-03 Bayer Cropscience Gmbh Verwendung von Hydroxyaromaten als Safener
WO2005030331A1 (en) 2003-09-26 2005-04-07 Fairfield Clinical Trials, Llc Combination antihistamine medication
US7186744B2 (en) 2003-11-13 2007-03-06 Allergan, Inc. Prostamides for the treatment of glaucoma and related diseases
CA2562219A1 (en) 2004-04-05 2005-10-20 Laboratorios Del Dr. Esteve, S.A. Active substance combination comprising a carbinol combined to at least an nsaid
DE102004025324A1 (de) 2004-05-19 2005-12-08 Boehringer Ingelheim Vetmedica Gmbh Flüssige Zubereitung für die Veterinärmedizin, Verfahren zu deren Herstellung und deren Verwendung
TWI276687B (en) 2004-06-30 2007-03-21 Univ Nat Cheng Kung Method for kinetic resolution of alpha-substituted acids and esters thereof by using papaya lipases
JP2008120684A (ja) * 2005-03-07 2008-05-29 Kumamoto Univ 抗アレルギー薬
US20070065374A1 (en) 2005-03-16 2007-03-22 Elan Pharma International Limited Nanoparticulate leukotriene receptor antagonist/corticosteroid formulations
US20060222692A1 (en) 2005-03-31 2006-10-05 Fairfield Clinical Trials Llc Method and compositions for transdermal administration of antimicrobial medications
EA013525B1 (ru) 2005-05-20 2010-06-30 Алантос-Фармасьютикалз Холдинг, Инк. Гетеробициклические ингибиторы металлопротеазы и их применение
CN100500149C (zh) * 2005-06-22 2009-06-17 晟德大药厂股份有限公司 白三烯素拮抗剂口服液组成
WO2008012603A1 (en) 2006-07-26 2008-01-31 Techfields Biochem Co. Ltd Positively charged water-soluble prodrugs of diflunisal and related compounds with very fast skin penetration rate
AU2006346195B2 (en) 2006-07-09 2013-03-07 Techfields Biochem Co. Ltd Positively charged water-soluble prodrugs of aspirin
HUE033687T2 (en) 2006-07-18 2017-12-28 Techfields Biochem Co Ltd Ibuprofen positively charged water soluble prodrugs with very fast skin penetration rates
ES2472545T3 (es) 2006-07-25 2014-07-01 Techfields Biochem Co. Ltd Profármacos de diclofenaco solubles en agua con carga positiva y con una tasa de penetración en piel muy rápida
PL2049482T3 (pl) * 2006-08-08 2016-04-29 Techfields Biochem Co Ltd Dodatnio naładowane rozpuszczalne w wodzie proleki kwasów arylo- i heteroarylooctowych o bardzo dużej szybkości przenikania przez skórę
US8458932B2 (en) 2006-08-11 2013-06-11 Alameda Technology, Llc Optical illusion device
CN101506161B (zh) 2006-08-15 2013-11-13 于崇曦 具有快速皮肤穿透速度的带正电荷的水溶性的芳基和杂芳基丙酸类前药
WO2008026776A1 (en) 2006-08-31 2008-03-06 Nanocarrier Co., Ltd. Transdermal composition, transdermal pharmaceutical composition and transdermal cosmetic composition comprising polymer micelle encapsulating active ingredient
CA2661649C (en) 2006-09-03 2014-12-30 Techfields Biochem Co. Ltd Positively charged water-soluble prodrugs of acetaminophen and related compounds with very fast skin penetration rate
ES2735287T3 (es) * 2006-09-03 2019-12-17 Techfields Biochem Co Ltd Profármacos solubles en agua cargados positivamente de ácidos n-arilantranílicos con muy rápida velocidad de penetración en la piel
WO2008041054A1 (en) 2006-10-02 2008-04-10 Techfields Biochem Co. Ltd Positively charged water-soluble prodrugs of prostaglandins and related compounds with very high skin penetration rates
EP2077991B1 (en) 2006-10-03 2014-02-26 Techfields Biochem Co. Ltd Positively charged water-soluble prodrugs of mustards and related compounds with very high skin penetration rates
CN101522692A (zh) 2006-10-11 2009-09-02 于崇曦 具有快速皮肤穿透速度的带正电荷的水溶性的昔康及其相关化合物的前药
CA2671938C (en) * 2006-12-10 2017-10-17 Chongxi Yu Transdermal delivery systems of beta-lactam antibiotics
PL2115140T3 (pl) * 2007-01-31 2017-03-31 Yu Dodatnio naładowane rozpuszczalne w wodzie proleki 1H-imidazo[4,5-c]chinolino-4-amin i powiązane związki o bardzo wysokich wskaźnikach penetracji przez skórę
US7781580B2 (en) * 2007-04-23 2010-08-24 Virginia Commonwealth University Stilbene derivatives as new cancer therapeutic agents
KR20210103586A (ko) * 2007-06-04 2021-08-23 테크필즈 인크 매우 높은 피부 및 막 침투율을 가지는 비스테로이드성 소염제(ｎｓａｉａ) 약물전구체 및 이들의 새로운 의약적 용도
US20090087425A1 (en) * 2007-08-10 2009-04-02 Topigen Pharmaceuticals Inc. Combination of nitroderivatized steroid and bronchodilator for treating respiratory disease
WO2009122187A2 (en) * 2008-04-03 2009-10-08 Cipla Limited Pharmaceutical composition
RU2630577C2 (ru) * 2008-12-04 2017-09-11 Чунси ЮЙ Композиции интенсивного проникновения и их применение
US8084896B2 (en) 2008-12-31 2011-12-27 Electro Scientific Industries, Inc. Monolithic stage positioning system and method
PL2427475T3 (pl) * 2009-05-08 2021-07-19 Techfields Biochem Co., Ltd. Kompozycje proleku o wysokim przenikaniu peptydów i związków powiązanych z peptydami
EP2440523A4 (en) 2009-06-10 2014-03-19 Chongxi Yu COMPOSITION WITH STRONG PENETRATION OR PRODRUGS FROM ANTIMICROBIA AND COMPOUNDS IN ANTIMICROBIA
TWI496577B (zh) * 2010-06-10 2015-08-21 Shanghai Techfields Biochem Co Ltd 抗菌劑和抗菌劑相關化合物的高滲透性前藥組合物
EP2407161A1 (en) * 2010-07-13 2012-01-18 Sanofi An antitumoral combination comprising ombrabulin and bevacizumab

Also Published As

Publication number Publication date
KR20200039029A (ko) 2020-04-14
IN2014KN02583A (enExample) 2015-05-08
EP2849738A1 (en) 2015-03-25
JP2019069948A (ja) 2019-05-09
ES2969344T3 (es) 2024-05-17
CA2872121C (en) 2023-02-14
KR102332837B1 (ko) 2021-12-01
RU2014150779A (ru) 2016-07-10
KR20240145521A (ko) 2024-10-07
JP2015516444A (ja) 2015-06-11
EP4356912A2 (en) 2024-04-24
CA3189252A1 (en) 2013-11-21
KR102232625B1 (ko) 2021-03-25
KR20220130239A (ko) 2022-09-26
MX2014013910A (es) 2015-06-04
US11857545B2 (en) 2024-01-02
CN111012914A (zh) 2020-04-17
BR112014028643A2 (pt) 2021-08-03
US20150072961A1 (en) 2015-03-12
MX378183B (es) 2025-03-10
KR20210034109A (ko) 2021-03-29
HK1207562A1 (en) 2016-02-05
EP2849738B1 (en) 2023-12-06
KR20210148394A (ko) 2021-12-07
HK1208633A1 (en) 2016-03-11
US20240131017A1 (en) 2024-04-25
EP2849738C0 (en) 2023-12-06
TW201402148A (zh) 2014-01-16
TWI658836B (zh) 2019-05-11
KR102309973B1 (ko) 2021-10-06
US20240226084A9 (en) 2024-07-11
ZA201407777B (en) 2020-01-29
KR102443057B1 (ko) 2022-09-14
AU2013262320B2 (en) 2018-02-22
US20190142818A1 (en) 2019-05-16
CA2872121A1 (en) 2013-11-21
HK1254324A1 (zh) 2019-07-19
US20240115562A1 (en) 2024-04-11
RU2683934C2 (ru) 2019-04-03
AU2018203612A1 (en) 2018-06-14
EP2849738A4 (en) 2016-03-30
CN107929743B (zh) 2023-09-01
KR20150020301A (ko) 2015-02-25
JP7235487B2 (ja) 2023-03-08
CN116898848A (zh) 2023-10-20
US11813256B2 (en) 2023-11-14
AU2013262320A1 (en) 2014-11-13
WO2013170655A1 (en) 2013-11-21
JP6445967B2 (ja) 2018-12-26
PL2849738T3 (pl) 2024-05-13
EP4356912A3 (en) 2024-10-30
CN104540504A (zh) 2015-04-22
CN107929743A (zh) 2018-04-20

Similar Documents

Publication Publication Date Title
BR112014028643A8 (pt) Profármaco de alta penetração, seus usos, e composição farmacêutica
BR112015022896A2 (pt) drogas de alta penetração e suas composições para o tratamento de doenças de parkinson
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
BR112015003590A8 (pt) Métodos para tratamento ou prevenção da asma por administração de um antagonista de il-4r
BR112015011171A2 (pt) compostos de pirrolopirimidina como inibidores da quinase
BR112017003346B8 (pt) Derivados de pirazolopiridina, seus usos, e composição farmacêutica
BR112015018168A2 (pt) inibidores de rock suaves
BR112014019052A8 (pt) Inibidores seletivos de cdk8/cdk19 e seu uso em métodos antimetastáticos e quimiopreventivos para câncer
BR112015027282A8 (pt) formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet
BR112015021549A2 (pt) inibidores de piridina cinase cdk9
BR112015023922A2 (pt) composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes
BR112015015477A2 (pt) derivados de 2,3-di-hidro-isoindol-1-ona e métodos de uso dos mesmos como inibidores de btk
BR112014010417A2 (pt) Métodos para o tratamento de cânceres com o uso de formulações orais de análogos de citidina
BR112016015818A2 (pt) Compostos e respectivos usos para tratar pacientes com células cancerosas mutantes em relação a ros1
BR112017026159A2 (pt) inibidores heterocíclicos de erk1 e erk2 e seu uso no tratamento de câncer
BR112015011158A2 (pt) triazolopirazina
BR112016024421A2 (pt) composição farmacêutica, cápsula e uso da composição farmacêutica
BR112014016648A2 (pt) derivados policíclicos, processo de preparação e uso farmacêutico dos mesmos
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
CU20140037A7 (es) Derivados de estra- 1,3,5(10), 16- tetraen- 3- carboximida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
BR112015022650A2 (pt) inibidores de cinase induzível por sal macrocíclico
PE20150353A1 (es) Derivados de estra-1,3,5(10),16-tetraeno 3-sustituidos, metodos para su preparacion, preparaciones farmaceuticas que los contienen, asi como su uso para la preparacion de medicamentos
BR112014016472A2 (pt) formulação farmacêutica estável para administração oral que compreende levocetirizina ou um sal farmaceuticamente aceitável da mesma e montelukast ou um sal farmaceuticamente aceitável do mesmo
BR112015023356A2 (pt) inibidores de quinase pirrol[2,3-b]piridina cdk9
BR112018072988A2 (pt) irinotecano lipossômico para uso no tratamento de câncer de pulmão de pequenas célula

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.